Jazz Pharmaceuticals PLC (JAZZ) EVP Michael Patrick Miller Sells 200 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, June 14th. The shares were sold at an average price of $176.53, for a total transaction of $35,306.00. Following the completion of the sale, the executive vice president now owns 25,972 shares in the company, valued at $4,584,837.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Patrick Miller also recently made the following trade(s):

Jazz Pharmaceuticals opened at $177.81 on Tuesday, MarketBeat reports. Jazz Pharmaceuticals PLC has a 1-year low of $128.58 and a 1-year high of $179.65. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.00 and a quick ratio of 2.88. The firm has a market capitalization of $10.69 billion, a P/E ratio of 18.06, a PEG ratio of 0.91 and a beta of 0.96.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported $2.98 EPS for the quarter, topping the Zacks’ consensus estimate of $2.78 by $0.20. Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. The firm had revenue of $444.61 million during the quarter, compared to analysts’ expectations of $435.69 million. During the same period in the previous year, the business posted $2.31 earnings per share. The company’s revenue for the quarter was up 18.2% compared to the same quarter last year. sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 11.65 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Suntrust Banks Inc. boosted its position in Jazz Pharmaceuticals by 6.9% during the first quarter. Suntrust Banks Inc. now owns 12,068 shares of the specialty pharmaceutical company’s stock worth $1,821,000 after purchasing an additional 775 shares during the period. Allianz Asset Management GmbH boosted its position in Jazz Pharmaceuticals by 2.2% during the first quarter. Allianz Asset Management GmbH now owns 111,701 shares of the specialty pharmaceutical company’s stock worth $16,865,000 after purchasing an additional 2,422 shares during the period. Summit Trail Advisors LLC boosted its position in Jazz Pharmaceuticals by 8,591.5% during the first quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock worth $102,000 after purchasing an additional 100,950 shares during the period. CIBC World Markets Inc. bought a new position in Jazz Pharmaceuticals during the first quarter worth $579,000. Finally, Xact Kapitalforvaltning AB boosted its position in Jazz Pharmaceuticals by 2.6% during the first quarter. Xact Kapitalforvaltning AB now owns 14,606 shares of the specialty pharmaceutical company’s stock worth $2,205,000 after purchasing an additional 374 shares during the period. 88.75% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently issued reports on JAZZ shares. Bank of America lifted their price objective on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 20th. BMO Capital Markets lifted their price objective on shares of Jazz Pharmaceuticals from $196.00 to $199.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. Piper Jaffray Companies reiterated a “buy” rating and issued a $201.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, March 1st. BidaskClub upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 13th. Finally, Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $128.58 to $163.75 in a report on Monday, March 19th. Four investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $182.49.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Leave a Reply

Your email address will not be published. Required fields are marked *